新型口服抗凝药引领未来.pptVIP

结论 在RECORD研究中，与标准治疗方案相比，利伐沙班的获益－风险比更佳 显著降低了下列复合终点事件的发生率: 症状性静脉血栓栓塞症（ VTE） 心血管事件 全因死亡 大出血 * Random effects approach is more conservative than fixed effects approach – yields wider confidence intervals allowing for trial heterogeneity. REFERENCE Wolowacz SE et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. Thromb Haemost 2009;101: 77-85. * Rivaroxaban is a novel, oral, direct Factor Xa inhibitor1 Rivaroxaban has predictable dose-proportional pharmacokinetics and pharmacodynamics in healthy subjects, and s